VON WILLEBRAND DISEASE (VWD), TYPE 2
Clinical trials for VON WILLEBRAND DISEASE (VWD), TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new VON WILLEBRAND DISEASE (VWD), TYPE 2 trials appear
Sign up with your email to follow new studies for VON WILLEBRAND DISEASE (VWD), TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bleeding disorder: first human trial of HMB-002 begins
Disease control Recruiting nowThis study tests a new medicine, HMB-002, in about 108 adults with von Willebrand disease (types 1 and 2). The goal is to check safety, how the drug moves in the body, and whether it helps control bleeding. It is the first time this drug is being tested in humans, starting with s…
Matched conditions: VON WILLEBRAND DISEASE (VWD), TYPE 2
Phase: PHASE1, PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to stop bleeding in rare blood disorder
Disease control Recruiting nowThis early-phase study tests a new drug called BT200 in 4-6 adults with type 2B von Willebrand disease who have low platelets and a history of bleeding. The drug is designed to raise von Willebrand factor and platelet levels, which may lower the risk of bleeding. Participants rec…
Matched conditions: VON WILLEBRAND DISEASE (VWD), TYPE 2
Phase: PHASE2 • Sponsor: Medical University of Vienna • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New study tracks bleeding in von willebrand disease to pave way for better treatments
Knowledge-focused Recruiting nowThis study is for people aged 16 to 70 with von Willebrand disease (VWD), a bleeding disorder. Researchers will collect information on bleeding events, treatments, and quality of life over time. The goal is to understand the real-world impact of VWD and use this data as a baselin…
Matched conditions: VON WILLEBRAND DISEASE (VWD), TYPE 2
Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC